Baseline demographics and characteristics. Data are no. ± SD, or n (%).
| PsA | n | No PsA | n | Unclear Diagnosis | n | |
|---|---|---|---|---|---|---|
| Age, yrs | 50.7 ± 13.4 | 137 | 54.5 ± 16.7 | 52 | 55.5 ± 12.9 | 22 |
| Male | 60 (44) | 137 | 17 (33) | 52 | 14 (64) | 22 |
| Yrs since psoriasis diagnosed | 19.9 ± 15.6 | 129 | 20.4 ± 17.4 | 49 | 24.6 ± 13.7 | 20 |
| Yrs of arthritis symptoms | 13.5 ± 13.8 | 137 | 13.0 ± 11.7 | 52 | 8.9 ± 11.1 | 22 |
| Prior PsA diagnosis | 91 (66) | 137 | 2 (4) | 52 | 2 (9) | 22 |
| CASPAR | 125 (93) | 134 | 6 (12) | 51 | 13 (59) | 22 |
| ASAS, axial | 33 (41) | 81 | 1 (5) | 19 | 2 (9) | 22 |
| Tender joint count | 10.4 ± 11.6 | 137 | 10.1 ± 17.0 | 52 | 3.3 ± 3.6 | 22 |
| Swollen joint count | 3.6 ± 6.1 | 137 | 0.3 ± 0.7 | 52 | 0.9 ± 1.2 | 22 |
| Nail pitting, current | 69 (51) | 134 | 20 (43) | 47 | 13 (62) | 21 |
| Psoriasis, current | 120 (88) | 137 | 43 (80) | 52 | 19 (86) | 22 |
| PGA | 1.5 ± 1.0 | 137 | 1.3 ± 0.8 | 52 | 2.0 ± 1.4 | 22 |
| Body surface area | 4.1 ± 9.1 | 137 | 3.1 ± 4.4 | 52 | 4.2 ± 6.1 | 22 |
| PsQOL | 8.4 ± 6.1 | 136 | 6.7 ± 6.1 | 51 | 6.9 ± 5.8 | 22 |
| MTX, current | 43 (31) | 137 | 8 (15) | 52 | 7 (32) | 22 |
| TNF inhibitor, current | 51 (37) | 137 | 11 (21) | 52 | 5 (23) | 22 |
| Ustekinumab, current | 6 (3) | 137 | 2 (4) | 52 | 0 | 22 |
| Other current immunomodulators* | 3 (2) | 137 | 1 (2) | 52 | 1 (5) | 22 |
↵* Other immunomodulators included cyclosporine, sulfasalazine, and hydroxychloroquine. PsA: psoriatic arthritis; CASPAR: ClASsification criteria for Psoriatic ARthritis; ASAS: Assessment of Spondyloarthritis International Society; PsQOL: psoriatic arthritis quality of life; PGA: physician global assessment; MTX: methotrexate; TNF: tumor necrosis factor.